secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001628280-26-028876
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum PIPE-791 Phase 1b shows safety, numeric pain reduction vs placebo
---------------------------------------------------------------------------

- 43-patient crossover trial met primary safety endpoint; no serious AEs, most common TEAEs: headache (n=3), fatigue (n=2).
- COAP patients: mean PI-NRS change -1.60 (PIPE-791) vs -1.27 (placebo) in Treatment Period 1.
- CLBP patients: mean PI-NRS change -1.33 (PIPE-791) vs -0.55 (placebo) in Treatment Period 1.
- Exploratory endpoints (≥30% pain reduction, KOOS) further supported positive PI-NRS trends.
- Company plans further evaluation of PIPE-791 for chronic pain; also in Phase 2 PROPEL-IPF (IPF).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026028876/0001628280-26-028876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026028876/ctnm-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-028876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer